## **ASSESSMENT OF THE BOARD OF DIRECTORS' USE OF THE FINANCIAL AUTHORISATION**

## LIST OF OUTSTANDING DELEGATIONS AND THEIR USE IN 2022 AND EARLY 2023 (UNTIL 13 MARCH 2023)

Type of authorisation	Purpose of the authorisation granted to the Board of Directors	Validity of the delegation	
Share buybacks	To buy Societe Generale shares	Granted by: AGM of 17 May 2022, 17 <sup>th</sup> resolution For a period of: 18 months Start date: 17 May 2022 Expiry date: 17 November 2023	
Capital increase	To increase the share capital with pre-emptive subscription rights through the issue of ordinary shares and/or securities giving access to the share capital	<b>Granted by:</b> AGM of 17 May 2022, 18 <sup>th</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	
	To increase the share capital through the incorporation of reserves, profits or premiums or any other item which may be incorporated in the share capital To increase the share capital with cancellation of pre-emptive	Granted by: AGM of 17 May 2022, 18 <sup>th</sup> resolution For a period of: 26 months Expiry date: 17 July 2024 Granted by: AGM of 17 May 2022, 19 <sup>th</sup> resolution	
	subscription rights through the issue of ordinary shares and/or securities giving access to the share capital	For a period of: 26 months Expiry date: 17 July 2024	
	To increase the share capital in order to remunerate contributions in kind consisting of equity securities or securities giving access to the share capital	<b>Granted by:</b> AGM of 17 May 2022, 20 <sup>th</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	
Capital increase in favour of employees	To increase the share capital through the issuance of ordinary shares or securities giving access to the share capital reserved for members of a Societe Generale company or Group savings plan	<b>Granted by:</b> AGM of 17 May 2022, 21 <sup>st</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	
Allocation of free shares	To allocate free shares, existing or to be issued, to regulated and assimilated persons	<b>Granted by:</b> AGM of 17 May 2022, 22 <sup>nd</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	
	To allocate free shares, existing or to be issued, to employees other than regulated and assimilated persons	<b>Granted by:</b> AGM of 17 May 2022, 23 <sup>rd</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	
Cancellation of shares	To cancel shares purchased as part of share buyback programmes	<b>Granted by:</b> AGM of 17 May 2022, 24 <sup>th</sup> resolution <b>For a period of:</b> 26 months <b>Expiry date:</b> 17 July 2024	

Limit	Use in 2022	Use in 2023 (until 13 March)
10% of the share capital at the completion date of the purchases.	Excluding the liquidity agreement: Societe Generale purchased 41,674,813 shares in order to cancel them. Societe Generale also purchased 1,000 shares for external growth, 3,496,050 shares in order to cover and honour the free share allocation plan for the benefit of employees and the Chairman of the Board of Directors and Chief Executive Officers. At 31 December 2022, no (0) shares were in the liquidity agreement's account.	were recorded in the liquidity
Nominal EUR 345.3 million for shares, i.e., 33% of the share capital at the date on which the authorisation was granted. <i>Note: this limit counts towards those set forth in resolutions 19 to 23 of the AGM of 17 May</i> 2022. Nominal EUR 6 billion shares for debt securities giving access to the share capital. <i>Note: this limit counts towards those set forth in resolutions 19 to 21 of the AGM of 17 May</i> 2022.	None	None
Nominal EUR 550 million.	None	None
Nominal EUR 104,640 million for shares, <i>i.e.</i> , 10% of the share capital at the date on which the authorisation was granted, being specified that the issue price of the shares will be equal to the weighted average of the closing prices of the three trading sessions on the Euronext Paris regulated market preceding the opening of the public offer, decreased by 10%. <i>Note:</i> this limit counts towards those issues conducted pursuant to resolution 20 of the AGM of 17 May 2022 In addition, the issues conducted pursuant to resolutions 19 and 20 count towards the total limit of nominal EUR 345.3 million set forth in resolution 18 of 18 May 2022. Nominal EUR 6 billion shares for debt securities giving access to the share capital. <i>Note:</i> this limit counts towards those issues conducted pursuant to resolutions 18, 19 and 21 of the AGM of 17 May 2022.	None	None
Nominal EUR 104,640 million for shares, <i>i.e.</i> , 10% of the share capital at the date on which the authorisation was granted. Note: this limit counts towards those issues conducted pursuant to resolution 19 of the AGM of 17 May 2022 In addition, the issues conducted pursuant to resolutions 19 and 20 count towards the total limit of nominal EUR 345.3 million set forth in resolution 18 of 17 May 2022.	None	None
Nominal EUR 15,696 million for shares, <i>i.e.</i> 1.5% of the capital at the date on which the authorisation was granted, being specified that (i) the issue price of the new shares will be equal to an average of the prices quoted on the regulated market of Euronext Paris during the twenty trading sessions preceding the date of the decision setting the opening date of subscription, minus a 20% discount; and that (ii) the Board of Directors will be able to convert all or part of the discount into a free allocation of shares or securities giving access to the share capital of the Company. Note: this limit, in addition to the nominal amount of securities that may be issued, count towards that set forth in resolution 18 of the AGM of 17 May 2022.		The Board approved the principle of the operation on 7 February 2023 for a nominal amount of EUR 15,696 million and for which the Chief Executive Officer received authorisation.
<ul> <li>1.2% of the share capital at the date on which the authorisation was granted, including a maximum of 0.5% of the share capital with a two-year vesting period for the payment of deferred variable compensation.</li> <li>Note: this limit counts towards that set forth in resolution 18 of the AGM of 17 May 2022.</li> <li>0.1% of the capital for the Chief Executive Officers.</li> <li>Note: this 0.1% limit counts towards those of 1.2% and 0.5% set forth in resolution 22 of the AGM of 17 May 2022.</li> </ul>	Not used. Note: at 10 March 2022, 1,903,466 shares were allocated, i.e., 0.23% of the share capital on the day of the allocation, corresponding to 0.22% of the share capital on 19 May 2020 (date of the vote at the AGM for which resolution 24 was used for this allocation).	At 8 March 2023, 2,340,990 shares were allocated, <i>i.e.</i> , 0.29% of the share capital on the day of the allocation, corresponding to 0.28% of the share capital on 17 May 2022 (date of the vote at the AGM for which resolution 22 was used for this allocation).
0.5% of the share capital on the authorisation date. Note: this limit counts towards that set forth in resolution 18 of the AGM of 17 May 2022.	Not used. Note: at 10 March 2022, 1,214,267 shares were allocated, i.e., 0.15% of the share capital on the day of the allocation, corresponding to 0.14% of the share capital on 19 May 2020 (date of the vote at the AGM for which resolution 25 was used for this allocation).	at 8 March 2023, 1,294,984 shares were allocated, <i>i.e.</i> , 0.16% of the share capital on the day of the allocation, corresponding to 0.15% of the share capital on 17 May 2022 (date of the vote at the AGM for which resolution 23 was used for this allocation).
10% of the total number of shares per 24-month period.	Reduction of share capital on 1 February 2022 <i>via</i> the cancellation of 16,247,062 shares.	Reduction of share capital on 1 February 2023 <i>via</i> the cancellation of 41,674,813 shares.